Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gram-negative infections: A systematic review.

Vardakas KZ, Athanassaki F, Pitiriga V, Falagas ME.

J Glob Antimicrob Resist. 2019 Jun;17:250-259. doi: 10.1016/j.jgar.2019.01.004. Epub 2019 Jan 15. Review.

PMID:
30658202
2.

Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences.

Falagas ME, Athanasaki F, Voulgaris GL, Triarides NA, Vardakas KZ.

Int J Antimicrob Agents. 2019 Jan;53(1):22-28. doi: 10.1016/j.ijantimicag.2018.09.013. Epub 2018 Sep 27. Review.

PMID:
30268576
3.

An update on adverse drug reactions related to β-lactam antibiotics.

Vardakas KZ, Kalimeris GD, Triarides NA, Falagas ME.

Expert Opin Drug Saf. 2018 May;17(5):499-508. doi: 10.1080/14740338.2018.1462334. Epub 2018 Apr 18. Review.

PMID:
29633867
4.

Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals.

Falagas ME, Skalidis T, Vardakas KZ, Voulgaris GL, Papanikolaou G, Legakis N; Hellenic TP-6076 Study Group.

Int J Antimicrob Agents. 2018 Aug;52(2):269-271. doi: 10.1016/j.ijantimicag.2018.03.009. Epub 2018 Mar 17.

PMID:
29559273
5.

Temporal Trends (1999-2015) in the Impact Factor of Biomedical Journals Published by US and EU Scientific Societies.

Falagas ME, Kyriakidou M, Spais G, Argiti E, Vardakas KZ.

Rambam Maimonides Med J. 2018 Apr 19;9(2). doi: 10.5041/RMMJ.10332.

6.

Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: A systematic review and meta-analysis.

Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME.

J Infect. 2018 Apr;76(4):321-327. doi: 10.1016/j.jinf.2018.02.002. Epub 2018 Feb 8. Review.

PMID:
29428226
7.

Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis.

Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME.

Int J Antimicrob Agents. 2018 Apr;51(4):535-547. doi: 10.1016/j.ijantimicag.2017.12.020. Epub 2017 Dec 27. Review.

PMID:
29288723
8.

Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.

Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME.

Lancet Infect Dis. 2018 Jan;18(1):108-120. doi: 10.1016/S1473-3099(17)30615-1. Epub 2017 Nov 5.

PMID:
29102324
9.

The dilemma of monotherapy or combination therapy in community-acquired pneumonia.

Vardakas KZ, Trigkidis KK, Apiranthiti KN, Falagas ME.

Eur J Clin Invest. 2017 Dec;47(12). doi: 10.1111/eci.12845. Epub 2017 Nov 9. Review.

PMID:
29027205
10.

Resistance phenotypes and susceptibility of contemporary Serratia isolates in the university hospital of Crete, Greece.

Samonis G, Vardakas KZ, Maraki S, Stamouli P, Mavromanolaki VE, Kofteridis DP, Falagas ME.

Infect Dis (Lond). 2017 Nov - Dec;49(11-12):847-853. doi: 10.1080/23744235.2017.1361546. Epub 2017 Aug 2.

PMID:
28768448
11.

Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis.

Vardakas KZ, Voulgaris GL, Samonis G, Falagas ME.

Int J Antimicrob Agents. 2018 Jan;51(1):1-9. doi: 10.1016/j.ijantimicag.2017.05.016. Epub 2017 Jun 29. Review.

PMID:
28669836
12.

In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece.

Maraki S, Vardakas KZ, Samonis G, Perdikis D, Mavromanolaki VE, Kofteridis DP, Falagas ME.

Future Microbiol. 2017 Jun;12:683-693. doi: 10.2217/fmb-2016-0216. Epub 2017 May 25.

PMID:
28540747
13.

Continuous or Extended Intravenous Administration of β-Lactam Antibiotics.

Falagas ME, Vardakas KZ.

Am J Respir Crit Care Med. 2017 Apr 15;195(8):1077-1078. doi: 10.1164/rccm.201610-2004LE. No abstract available.

PMID:
28409679
14.

Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.

Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ; Hellenic Cefiderocol Study Group.

J Antimicrob Chemother. 2017 Jun 1;72(6):1704-1708. doi: 10.1093/jac/dkx049.

PMID:
28369471
15.

In vitro susceptibility and resistance phenotypes in contemporary Citrobacter isolates in a University Hospital in Crete, Greece.

Maraki S, Vardakas KZ, Mavromanolaki VE, Kyriakidou M, Spais G, Kofteridis DP, Samonis G, Falagas ME.

Infect Dis (Lond). 2017 Jul;49(7):532-539. doi: 10.1080/23744235.2017.1297896. Epub 2017 Mar 9.

PMID:
28276281
16.

Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis.

Vardakas KZ, Trigkidis KK, Falagas ME.

Clin Microbiol Infect. 2017 Apr;23(4):234-241. doi: 10.1016/j.cmi.2016.12.002. Epub 2016 Dec 10. Review.

17.

Colistin loading dose: evaluation of the published pharmacokinetic and clinical data.

Vardakas KZ, Rellos K, Triarides NA, Falagas ME.

Int J Antimicrob Agents. 2016 Nov;48(5):475-484. doi: 10.1016/j.ijantimicag.2016.08.009. Epub 2016 Sep 28. Review.

PMID:
27743779
18.

Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.

Vardakas KZ, Falagas ME.

Int J Antimicrob Agents. 2017 Feb;49(2):233-238. doi: 10.1016/j.ijantimicag.2016.07.023. Epub 2016 Sep 16. Review.

PMID:
27686609
19.

The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?

Falagas ME, Mavroudis AD, Vardakas KZ.

Expert Rev Anti Infect Ther. 2016 Aug;14(8):747-63. doi: 10.1080/14787210.2016.1204911. Review.

PMID:
27400643
20.

Impact of oseltamivir use on the reduction of complications in patients with influenza: a prospective study.

Vardakas KZ, Theocharis G, Tansarli GS, Rafailidis P, Falagas ME.

Arch Virol. 2016 Sep;161(9):2511-8. doi: 10.1007/s00705-016-2941-5. Epub 2016 Jul 1.

PMID:
27368992
21.

Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis.

Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME.

Int J Antimicrob Agents. 2016 Jul;48(1):1-10. doi: 10.1016/j.ijantimicag.2016.03.008. Epub 2016 Apr 27. Review.

PMID:
27216385
22.

Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature.

Vardakas KZ, Legakis NJ, Triarides N, Falagas ME.

Int J Antimicrob Agents. 2016 Apr;47(4):269-85. doi: 10.1016/j.ijantimicag.2016.02.001. Epub 2016 Feb 24. Review.

PMID:
27013000
23.

Fosfomycin.

Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ.

Clin Microbiol Rev. 2016 Apr;29(2):321-47. doi: 10.1128/CMR.00068-15. Review.

24.

Rapid molecular diagnostic tests in patients with bacteremia: evaluation of their impact on decision making and clinical outcomes.

Vardakas KZ, Anifantaki FI, Trigkidis KK, Falagas ME.

Eur J Clin Microbiol Infect Dis. 2015 Nov;34(11):2149-60. doi: 10.1007/s10096-015-2466-y. Epub 2015 Sep 2. Review.

PMID:
26329038
25.

Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence.

Falagas ME, Vardakas KZ, Roussos NS.

Int J Antimicrob Agents. 2015 Sep;46(3):231-41. doi: 10.1016/j.ijantimicag.2015.04.002. Epub 2015 May 15. Review.

PMID:
26070662
26.

Clostridium difficile in Crete, Greece: epidemiology, microbiology and clinical disease.

Samonis G, Vardakas KZ, Tansarli GS, Dimopoulou D, Papadimitriou G, Kofteridis DP, Maraki S, Karanika M, Falagas ME.

Epidemiol Infect. 2016 Jan;144(1):161-70. doi: 10.1017/S0950268815000837. Epub 2015 May 20.

PMID:
25989816
27.

Tigecycline for carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit.

Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E.

Infect Dis (Lond). 2015;47(10):751-3. doi: 10.3109/23744235.2015.1049659. Epub 2015 May 19. No abstract available.

PMID:
25986909
28.

Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.

Zhang X, Falagas ME, Vardakas KZ, Wang R, Qin R, Wang J, Liu Y.

J Thorac Dis. 2015 Apr;7(4):603-15. doi: 10.3978/j.issn.2072-1439.2015.03.10.

29.

Tetracyclines for multidrug-resistant Acinetobacter baumannii infections.

Falagas ME, Vardakas KZ, Kapaskelis A, Triarides NA, Roussos NS.

Int J Antimicrob Agents. 2015 May;45(5):455-60. doi: 10.1016/j.ijantimicag.2014.12.031. Epub 2015 Feb 16. Review.

PMID:
25801348
30.

Antimicrobial-impregnated and -coated shunt catheters for prevention of infections in patients with hydrocephalus: a systematic review and meta-analysis.

Konstantelias AA, Vardakas KZ, Polyzos KA, Tansarli GS, Falagas ME.

J Neurosurg. 2015 May;122(5):1096-112. doi: 10.3171/2014.12.JNS14908. Epub 2015 Mar 13. Review.

PMID:
25768831
31.

Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: A systematic review.

Falagas ME, Trigkidis KK, Vardakas KZ.

Int J Antimicrob Agents. 2015 Mar;45(3):221-33. doi: 10.1016/j.ijantimicag.2014.10.008. Epub 2014 Nov 6. Review.

PMID:
25533880
32.

Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit.

Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E.

J Infect. 2015 Jun;70(6):592-9. doi: 10.1016/j.jinf.2014.11.003. Epub 2014 Nov 15.

PMID:
25447713
33.

Antistaphylococcal penicillins versus cephalosporins for definitive treatment of meticillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.

Vardakas KZ, Apiranthiti KN, Falagas ME.

Int J Antimicrob Agents. 2014 Dec;44(6):486-92. doi: 10.1016/j.ijantimicag.2014.09.002. Epub 2014 Sep 19. Review.

PMID:
25311850
34.

Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.

Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ.

Emerg Infect Dis. 2014 Jul;20(7):1170-5. doi: 10.3201/eid2007.121004.

35.

Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections.

Samonis G, Vardakas KZ, Kofteridis DP, Dimopoulou D, Andrianaki AM, Chatzinikolaou I, Katsanevaki E, Maraki S, Falagas ME.

Infection. 2014 Aug;42(4):721-8. doi: 10.1007/s15010-014-0635-z. Epub 2014 Jun 10.

PMID:
24912861
36.

Vacuum-assisted closure versus closure without vacuum assistance for preventing surgical site infections and infections of chronic wounds: a meta-analysis of randomized controlled trials.

Tansarli GS, Vardakas KZ, Stratoulias C, Peppas G, Kapaskelis A, Falagas ME.

Surg Infect (Larchmt). 2014 Aug;15(4):363-7. doi: 10.1089/sur.2013.028. Epub 2014 May 8. Review.

PMID:
24810943
37.

Trends of isolation of intrinsically resistant to colistin Enterobacteriaceae and association with colistin use in a tertiary hospital.

Samonis G, Korbila IP, Maraki S, Michailidou I, Vardakas KZ, Kofteridis D, Dimopoulou D, Gkogkozotou VK, Falagas ME.

Eur J Clin Microbiol Infect Dis. 2014 Sep;33(9):1505-10. doi: 10.1007/s10096-014-2097-8. Epub 2014 Apr 15.

PMID:
24798249
38.

Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.

Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS.

Int J Antimicrob Agents. 2014 Jul;44(1):1-7. doi: 10.1016/j.ijantimicag.2014.01.006. Epub 2014 Feb 6. Review.

PMID:
24602499
39.

Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis.

Korbila IP, Tansarli GS, Karageorgopoulos DE, Vardakas KZ, Falagas ME.

Expert Rev Anti Infect Ther. 2013 Jun;11(6):585-95. doi: 10.1586/eri.13.44.

PMID:
23750730
40.

Impact of vacuum-assisted closure (VAC) therapy on clinical outcomes of patients with sternal wound infections: a meta-analysis of non-randomized studies.

Falagas ME, Tansarli GS, Kapaskelis A, Vardakas KZ.

PLoS One. 2013 May 31;8(5):e64741. doi: 10.1371/journal.pone.0064741. Print 2013.

41.

A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies.

Samonis G, Vardakas KZ, Maraki S, Tansarli GS, Dimopoulou D, Kofteridis DP, Andrianaki AM, Falagas ME.

Support Care Cancer. 2013 Sep;21(9):2521-6. doi: 10.1007/s00520-013-1816-5. Epub 2013 Apr 27.

PMID:
23625018
42.

Reply to Soman et al and Frippiat et al.

Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ.

Clin Infect Dis. 2013 Jul;57(2):325-7. doi: 10.1093/cid/cit202. Epub 2013 Apr 1. No abstract available.

PMID:
23547167
43.

Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review.

Falagas ME, Tansarli GS, Kapaskelis A, Vardakas KZ.

Expert Rev Anti Infect Ther. 2013 Jan;11(1):69-78. doi: 10.1586/eri.12.149. Review.

PMID:
23428103
44.

β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.

Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME.

Int J Antimicrob Agents. 2013 Apr;41(4):301-10. doi: 10.1016/j.ijantimicag.2012.12.006. Epub 2013 Feb 12. Review.

PMID:
23410791
45.

Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review.

Vardakas KZ, Kontopidis I, Gkegkes ID, Rafailidis PI, Falagas ME.

Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):711-21. doi: 10.1007/s10096-012-1807-3. Epub 2013 Jan 20. Review.

PMID:
23334662
46.

Understanding of statistical terms routinely used in meta-analyses: an international survey among researchers.

Mavros MN, Alexiou VG, Vardakas KZ, Falagas ME.

PLoS One. 2013;8(1):e47229. doi: 10.1371/journal.pone.0047229. Epub 2013 Jan 11.

47.

Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug?

Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME.

J Infect. 2013 May;66(5):401-14. doi: 10.1016/j.jinf.2012.10.028. Epub 2012 Nov 6. Review.

PMID:
23142195
48.

Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.

Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ.

Clin Infect Dis. 2013 Jan;56(2):272-82. doi: 10.1093/cid/cis857. Epub 2012 Oct 16. Review.

PMID:
23074314
49.

Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression.

Mavros MN, Tansarli GS, Vardakas KZ, Rafailidis PI, Karageorgopoulos DE, Falagas ME.

Int J Antimicrob Agents. 2012 Dec;40(6):496-509. doi: 10.1016/j.ijantimicag.2012.07.023. Epub 2012 Oct 12. Review.

PMID:
23068600
50.

Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis.

Vardakas KZ, Konstantelias AA, Loizidis G, Rafailidis PI, Falagas ME.

Int J Infect Dis. 2012 Nov;16(11):e768-73. doi: 10.1016/j.ijid.2012.07.010. Epub 2012 Aug 22. Review.

Supplemental Content

Loading ...
Support Center